Health Condition 1: J459- Other and unspecified asthma
Conditions
Interventions
Intervention1: Fluticasone propionate inhalation aerosol USP 44 mcg (Glenmark Pharmaceuticals Ltd.): Dosage Form: Metered dose Inhalation Aerosol
Dosage Frequency 44 mcg (two inhalations
twice daily (i.e. morning & evening approximately. 12 h apart,
Mode of Administration: Oral inhalation
Control Intervention1: FLOVENT HFA 44 mcg: Dosage Form: Metered dose Inhalation Aerosol
Dosage
twice daily (i.e. morning & evening approximately. 12 h apart,
Mode of Administration: Oral inhalation
Control Intervention2: Matching Placebo inhaler: Dosage Form: Metered dose Inhalation Aerosol
twice daily (i.e. morning & evening approximately. 12 h apart,
Mode of Administration: Oral inhalation
Sponsors
Glenmark Pharmaceuticals Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adult male or female subjects aged between 18 to 65 years of age (both ages inclusive) 2. Diagnosis of asthma for, at least 12 months prior to screening 3. Pre-bronchodilator FEV1 of more than or equal to 45 % and less than or equal to 85 % of the predicted normal value. 4. Subjects should be stable on their chronic asthma treatment regimen for at least 4 weeks prior to screening 5. Currently non-smoking; 6. More than or equal to 15 % reversibility of FEV1 within 30 min following 360 mcg of Albuterol/salbutamol inhalation (pMDI) at screening 7. Ability to discontinue their asthma controller medication safely 8. Ability to replace short-acting ß agonists (SABAs) ongoing at screening with Albuterol/salbutamol inhaler. 9. Women of childbearing potential must be willing to consistently use an appropriate method of contraception. 10. Willingness to give their written informed consent to participate in the study. 11. Is willing to comply with all aspects of the protocol. 12. Ability to follow training given for study related procedures and assessments in the opinion of the Investigator.
Exclusion criteria
Exclusion criteria: 1. Patients with life-threatening asthma, 2. Significant respiratory disease other than asthma 3. Evidence or history of clinically significant medical, surgical or psychiatric disease or laboratory abnormalities. 4. Known hypersensitivity to any sympathomimetic drug. 5. Subjects receiving ß2-blockers, anti-arrhythmics, anti-depressants, and/or monoamine oxidase inhibitors within 4 weeks prior to the screening. 6. Viral or bacterial, upper or lower respiratory tract infection, or sinus, or middle ear infection within 4 weeks prior to the screening visit 7. Subjects who required biologic agents for asthma systemic or oral corticosteroids (for any reason), within the past 6 months prior to screening 8. Evidence or history of oral candidiasis, active tuberculosis, hypercorticism, adrenal suppression, or eye problems. 9. Female subjects who are pregnant or breast-feeding or planning to be pregnant 10. Currently enrolled in another clinical study or used any investigational product (study drug), study drug, or device within 30 days or 5 elimination half-lives, whichever is longer, preceding informed consent 11 Consumes excessive amounts of alcohol, abuses drugs, or has any condition that would compromise compliance with this protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in FEV1Timepoint: From Baseline to last day of 4-week treatment period | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety of the study drug as assessed by treatment emergent adverse events (TEAEs) and clinically significant change in 12-lead ECGs, physical examination details, vital signs and laboratory investigationsTimepoint: From the start of treatment till End of study | — |
Countries
India, United States of America
Contacts
Public ContactMahesh Deshpande
Glenmark Research Centre
Outcome results
None listed